Wet AMD

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco.

This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

A panel of retina specialists weighed in on the dosing intervals when using of faricimab for the treatment of neovascular AMD in the clinical practice setting. Do you agree with them?

The experimental gene therapy was administered as a treatment in part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Adverum Biotechnologies, Inc. provided an update on the company’s ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.

RGX-314, an investigational formulation being developed in collaboration with AbbVie, may be a potential one-time treatment for nAMD, diabetic retinopathy, and other chronic retinal conditions.

According to Clearside Biomedical, a pair of presentations at the ASRS annual meeting in Seattle highlight CLS-AX as a potential treatment option for wet AMD treatment with a new mechanism of action and the possibility for longer duration of effect than current therapies.

Going forward, sozinibercept will be the official moniker of OPT-302, which holds fast track designation from the US Food and Drug Administration (FDA).

Clearside Biomedical developing a long-acting therapy for the treatment of retinal diseases, including wet AMD.

According to 4DMT, the Dose Expansion stage of the PRISM trial is a multicenter, randomized study designed to evaluate the safety and efficacy of 4D-150 at two different dose levels.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.

Expert retina specialists discuss recent developments in the treatment landscape for geographic atrophy (GA) and the future management of patients with coexisting neovascular AMD and GA.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their perspectives on biosimilars in the treatment of neovascular AMD and DME, emphasizing how their cost will affect their uptake.

Adrienne Scott, MD, and Prethy Rao, MD, MPH, discuss implementation of step therapy in neovascular age-related macular degeneration and diabetic macular edema without compromising vision outcomes.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

Expert retina specialists discuss the OPT-302 study and the challenges presented when using 2 agents in tandem to treat diabetic macular edema.

Retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301.